SDMA is more than just a chronic kidney disease biomarker. It is more sensitive and more reliable than creatinine and is an earlier indicator of progressive kidney function loss due to acute or chronic disease. SDMA provides value in wellness testing and in evaluations other than wellness examinations, a topic that will include analysis of a new data set. An increased SDMA can also be an indicator for concurrent diseases that can secondarily impact kidney function and should be investigated. Clinical case examples will be discussed that illustrate the expanded clinical utility of SDMA.